Shenzhen Hygieia Biotechnology Co., Ltd. Engaged in the research of biocatalysis and sythetic bilogy, focusing on the R & D, production and sales of new dietary nutritional supplement raw materials and medical beauty raw material.

In 2019, we realized the industrialization of high quality Nicotinamide Mononucleotide (NMN) based on a new enzymatic process, with a number of independent intellectual property rights, our product has been approved by US, Japan, EU ect...Test lab.

In the future, Hygieia will introduce computer AI-design technology into protein artificial assembly, and combine with new enzyme engineering technology to achieve more technological breakthroughs.

In addition, we actively participate in the research projects with domestic and foreign research institutions, help promote the progress of NMN in clinical research, continuously expand the research of NMN application and explore related indications, and provide more basic research data support for NMN industry chain!

We focus on anti-aging, focus on health, and share the future with you!

* **Raw Material***

1. Safety Assement of NMN raw material

Since 2020, Hygieia has started the Safety Assessment of NMN raw materials, contributing to the compliance, legality and safety verification of NMN.

* Acute toxicology experiment - Completed, and the result is non-toxic;

* Bacterial reverse mutation test - In progress

* Mammalian erythrocyte micronucleus test - In progress

* In vitro mammalian cell chromosome aberration test - In progress

* 90 day oral toxicity test in rats - In progress

* Teratogenicity test in rats - In progress

2. Quality of our product:

1) The safety of microorganism and heavy metal meets the requirements of national standard.

2) The raw material passed the acute toxicity test, which was actually non-toxic.

3) A number of third-party testing institutions (CTI, Intertek, Eurofins) measured purity ≥ 99.7%.